help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M. H.
Right arrow Articles by Pazdur, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M. H.
Right arrow Articles by Pazdur, R.
The Oncologist, Vol. 6, No. 1, 4-11, February 2001
© 2001 AlphaMed Press

FDA COMMENTARY

Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene

Martin H. Cohen, Steven Hirschfeld, Susan Flamm Honig, Amna Ibrahim, John R. Johnson, James J. O'Leary, Robert M. White, Grant A. Williams, Richard Pazdur

Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Martin H. Cohen, M.D., Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, WOC-II, 1451 Rockville Pike, Rockville, Maryland 20852, USA. Telephone 301-594-2473; Fax: 301-594-0498; e-mail: cohenm{at}cder.fda.gov

This report summarizes information on drugs recently approved by the Food and Drug Administration, Office of Drug Evaluation I, Division of Oncology Drug Products. Five applications supporting new claims will be discussed: TrisenoxTM (arsenic trioxide) for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose disease is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression; Nolvadex® (tamoxifen citrate) in women with ductal carcinoma in situ, following breast surgery and radiation, to reduce the risk of invasive breast cancer; Arimidex® (anastrazole) for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer; Taxol® (paclitaxel), 175 mg/m2 by 3 h infusion in combination with cisplatin for first-line treatment of advanced ovarian cancer; and Targretin® gel (bexarotene) for the topical treatment of cutaneous lesions in patients with stage IA and IB cutaneous T-cell lymphoma who have not tolerated other therapies or who have refractory or persistent disease.

Information provided includes rationale for drug development, study design, efficacy and safety results, and pertinent literature references.

Key Words. Arsenic trioxide • Tamoxifen citrate • Anastrazole • Paclitaxel • Bexarotene




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
I. P. Uray, Q. Shen, H.-S. Seo, H. Kim, W. W. Lamph, R. P. Bissonnette, and P. H. Brown
Rexinoid-induced Expression of IGFBP-6 Requires RAR{beta}-dependent Permissive Cooperation of Retinoid Receptors and AP-1
J. Biol. Chem., January 2, 2009; 284(1): 345 - 353.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan
Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Lichtman, L. Balducci, and M. Aapro
Geriatric Oncology: A Field Coming of Age
J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
W. Yang, J. Ge, H. Liu, K. Zhao, X. Liu, X. Qu, W. Li, Y. Huang, A. Sun, and Y. Zou
Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model
Cardiovasc Res, December 1, 2006; 72(3): 483 - 493.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Murillo Jr. and J. Koeller
Chemotherapy Given Near the End of Life by Community Oncologists for Advanced Non-Small Cell Lung Cancer
Oncologist, November 1, 2006; 11(10): 1095 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. Weiss, C. Langer, R. Rosell, N. Hanna, F. Shepherd, L. H. Einhorn, B. Nguyen, S. Paul, P. McAndrews, P. A. Bunn Jr, et al.
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 20, 2006; 24(27): 4405 - 4411.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?
J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations
J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Powles
Breast Cancer Prevention
Oncologist, February 1, 2002; 7(1): 60 - 64.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Edelman
New Directions in the Treatment of Non-Small Cell Lung Cancer: An Overview
Oncologist, February 1, 2001; 6(2008): 1 - 3.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.